Medindia

X

Project Hope to Lead First-Ever, Large-Scale Diabetes Education and Training Initiative in India

Monday, November 12, 2007 General News J E 4
Advertisement
Corporate Partners BD, Eli Lilly and Company, and Bayer Diabetes Care to Sponsor Four-Year Program Intended to Educate More Than 5,000 Health Care Professionals to Address the Needs of Nearly 41 Million People with Diabetes in India



MILLWOOD, Va., Nov. 12 /PRNewswire-USNewswire/ -- The India Diabetes Educator Project, the first large-scale initiative to train and educate health care professionals in India about the disease, was announced today by Project HOPE, an international health education and humanitarian assistance organization, and its corporate partners, BD, Eli Lilly and Company, and Bayer Diabetes Care. The four-year, multi-million dollar collaborative program is designed to help health care workers in India reduce morbidity and mortality related to diabetes and to combat the rapidly growing threat of diabetes there. With an estimated 40.9 million people currently living with the condition, India leads the world in the prevalence of diabetes (1).



The India Diabetes Educator Project offers a comprehensive and sustainable approach that will provide diabetes training to more than 5,000 health care professionals, including nurses, dieticians and nutritionists in India. The project includes mentoring support for newly trained Diabetes Educators and also addresses the role of the educator in empowering the patient to take responsibility for daily self-care and to help prevent the onset of diabetes among those at-risk. The training will be based on the International Curriculum for Diabetes Health Professional Education developed by the International Federation Consultative Section on Diabetes Education (IDF-DECS) curriculum, adapted for use in India. Implementation of this curriculum will help establish a consistent and standardized protocol for diabetes treatment throughout the country, with the goal of improving patient quality of life and increasing positive self-care behaviors and control of diabetes.



"India is at the forefront of the growing global diabetes epidemic and is in urgent need of trained Diabetes Educators," said John P. Howe III, M.D., President and CEO of Project HOPE. "With the support of our corporate partners, Project HOPE can make meaningful contributions to improving levels of professional care and patient self-management for many hundreds of thousands of people in India living with diabetes."



There is a great need for trained health care professionals in India, including nurses, dieticians and nutritionists, to educate patients about proper diabetes care. In India's urban areas approximately 12 percent of adults live with diabetes, compared to only seven percent in the United States (CDC data, 2005) and the United Kingdom. Additionally, research has identified a genetic factor that predisposes Indians to the development of diabetes (2). Inadequate control of diabetes can be associated with serious medical complications, including blindness, stroke, heart disease and kidney failure. In fact, diabetes is the second most common cause of blindness in India, surpassed only by cataracts.



Project HOPE, BD, Eli Lilly and Company, and Bayer Diabetes Care bring over a decade of successful collaboration on diabetes education interventions to this effort. The skills, resources and experience of Project HOPE and partners, combined with the expertise of the IDF-DECS curriculum, will work to tackle the challenges of diabetes education, prevention and treatment in India.



"India is one of the largest populations with the highest prevalence of diabetes worldwide, and can benefit significantly from higher levels of diabetes self-management education, care, and treatment services," said William Marshall, President, BD Medical-Diabetes Care.



"Success in treating diabetes will not come from pharmaceutical interventions alone," said Lorenzo Tallarigo, M.D., President of Interna
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Lexicon Files Investigational New Drug Application...
S
Skystar Bio-Pharmaceutical Announces Conference Ca...